Crinetics to present initial atumelnant Phase 2 data in CAH and Cushing's at ENDO 2024

Crinetics Pharmaceuticals, Inc.

Five abstracts, four late-breaking, to be presented at ENDO 2024 (June 1-4, Boston).
Initial Phase 2 TouCAHn data: atumelnant shows rapid, profound reductions in androstenedione and 17-hydroxyprogesterone in classic congenital adrenal hyperplasia.
Phase 1b/2a data on atumelnant in ACTH-dependent Cushing's shows first evidence of rapid, sustained cortisol reductions.
Phase 3 PATHFNDR-2 paltusotine data in medically untreated acromegaly patients to be presented; PATHFNDR-1 patient-reported symptoms and long-term safety also featured.
Crinetics plans to submit paltusotine NDA later in 2024; CEO cites major milestone for pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.